Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ACCELERON PHARMA INC.

(XLRN)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
06/15/2021 06/16/2021 06/17/2021 06/18/2021 06/21/2021 Date
128.71(c) 126.74(c) 127.32(c) 128.24(c) 128.3 Last
245 161 153 253 174 311 579 944 156 515 Volume
-1.79% -1.53% +0.46% +0.72% +0.05% Change
More quotes
Financials (USD)
Sales 2021 142 M - -
Net income 2021 -226 M - -
Net cash position 2021 592 M - -
P/E ratio 2021 -34,2x
Yield 2021 -
Sales 2022 218 M - -
Net income 2022 -158 M - -
Net cash position 2022 511 M - -
P/E ratio 2022 -48,7x
Yield 2022 -
Capitalization 7 784 M 7 784 M -
EV / Sales 2021 50,7x
EV / Sales 2022 33,4x
Nbr of Employees 312
Free-Float 87,8%
More Financials
Company
Acceleron Pharma Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta (TGF-beta), protein superfamily. It has four internally discovered therapeutic candidates that... 
Sector
Biotechnology & Medical Research
Calendar
06/22 | 08:00amR&D Day
More about the company
Ratings of Acceleron Pharma Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C
More Ratings
All news about ACCELERON PHARMA INC.
06/17ACCELERON PHARMA  : Reblozyl was generally well tolerated and improvements in he..
PU
06/17ACCELERON PHARMA INC  : Other Events, Financial Statements and Exhibits (form 8-..
AQ
06/08INSIDER TRENDS : Insider at Acceleron Pharma Sells for Tax Adds to 90-Day Sellin..
MT
06/08ACCELERON PHARMA  : to Host Virtual Research and Development (R&D) Day on June 2..
BU
05/19ACCELERON PHARMA  : ATS 2021 International Conference
PU
05/19ACCELERON PHARMA  : Data presented show maintained or improved responses in mult..
PU
05/19ACCELERON PHARMA INC  : Other Events, Financial Statements and Exhibits (form 8-..
AQ
05/19ACCELERON PHARMA  : For The First Time, FDA Cites Sponsor For Failure To Submit ..
AQ
05/19ACCELERON PHARMA  : Presents Preliminary Data from the SPECTRA Phase 2 Trial of ..
BU
05/19ACCELERON PHARMA  : Presents Interim Results from the Open-label Extension of th..
BU
05/12ACCELERON PHARMA  : Announces Presentations on REBLOZYL® (luspatercept-aamt) at ..
BU
05/11ACCELERON PHARMA  : to Host Conference Call and Webcast to Review Clinical Trial..
BU
05/10CLINICAL TRIALS : Does FDA's Notice To Acceleron Signal A New Era Of Enforcement..
AQ
05/07ACCELERON PHARMA  : Oppenheimer Adjusts Acceleron Pharma PT to $141 From $140, M..
MT
05/07ACCELERON PHARMA  : Q1 Earnings Call
PU
More news
News in other languages on ACCELERON PHARMA INC.
2020WALL STREET STOCK EXCHANGE : Les valeurs à suivre à Wall Street
2018ACCELERON PHARMA  : Die Celgene Corporation und Acceleron Pharma geben bei der A..
2018ASH 2018 : Celgene Corporation e Acceleron Pharma annunciano i risultati dello s..
2014ACCELERON PHARMA  : Studienergebnisse im Rahmen der 19. Jahresversammlung der Eu..
2014ACCELERON PHARMA  : Présentation, à l'occasion du 19ème congrès annuel de l'Asso..
More news
Analyst Recommendations on ACCELERON PHARMA INC.
More recommendations
Chart ACCELERON PHARMA INC.
Duration : Period :
Acceleron Pharma Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ACCELERON PHARMA INC.
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 14
Average target price 153,64 $
Last Close Price 128,24 $
Spread / Highest target 56,0%
Spread / Average Target 19,8%
Spread / Lowest Target -13,4%
EPS Revisions
Managers and Directors
NameTitle
Habib J. Dable President, Chief Executive Officer & Director
Kevin F. McLaughlin Chief Financial Officer, Treasurer & Senior VP
Francois Nader Non-Executive Chairman
Ravindra Kumar Chief Scientific Officer & Senior Vice President
Jay T. Backstrom Executive VP & Head-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
ACCELERON PHARMA INC.0.23%7 784
GILEAD SCIENCES, INC.14.33%83 541
WUXI APPTEC CO., LTD.24.70%63 775
REGENERON PHARMACEUTICALS11.35%55 705
BIONTECH SE160.57%51 304
VERTEX PHARMACEUTICALS-20.52%48 628